Pygopus2 ameliorates mesenteric adipocyte poor differentiation to alleviate Crohn's disease -like colitis via the

Jing Li1, Lugen Zuo2, Zhijun Geng3

  • 1Department of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.

Cell Proliferation
|June 16, 2022
PubMed
Abstract

Insights

Pygopus2 (Pygo2) promotes inflammation in Crohn's disease mesenteric fat by hindering adipocyte differentiation. Inhibiting Pygo2 improves this in a mouse model, suggesting a therapeutic target for Crohn's disease.

Area of Science:

  • Gastroenterology
  • Immunology
  • Cell Biology

Background:

  • Crohn's disease (CD) involves inflammation in mesenteric adipose tissue (MAT), linked to poorly differentiated adipocytes.
  • Pygopus2 (Pygo2) is identified as a key negative regulator of adipocyte differentiation.

Purpose of the Study:

  • To investigate Pygo2's role in CD mesenteric lesions.
  • To evaluate the therapeutic potential of Pygo2 knockdown in a CD mouse model (Il-10-/- mice).

Main Methods:

  • Measured Pygo2 expression in MAT from CD patients and Il-10-/- mice via immunohistochemistry.
  • Utilized lentiviral transfection to modulate Pygo2 in Il-10-/- mice to assess effects on adipocyte differentiation and inflammation.
  • Investigated the underlying molecular mechanism involving the Axin2/GSK3β pathway.

Main Results:

  • Elevated Pygo2 expression in MAT of CD patients and Il-10-/- mice correlated with poor adipocyte differentiation and inflammation.
  • Pygo2 knockdown significantly reduced colitis severity in Il-10-/- mice.
  • Downregulating Pygo2 promoted adipocyte differentiation and reduced inflammation in vitro and in vivo, partly via the Axin2/GSK3β pathway.

Conclusions:

  • Increased Pygo2 expression is associated with poor mesenteric adipocyte differentiation and inflammatory features in CD.
  • Pygo2 inhibition offers a potential therapeutic strategy for CD-like colitis by improving mesenteric lesions through the Axin2/GSK3β pathway.